Company Introduction

Juventas Cell Therapy Ltd (hereinafter referred as to JUVENTAS) is a biopharmaceutical company established in 2018, focusing on the research and development of innovative immune cell therapy products. JUVENTAS regards clinical requirements as the lodestar, constructs innovative research pipelines, and possesses effective development transformation platforms.Through professional and sophisticated production, QA, and QC system, we produce safe, highly-effective, and accessible immune cell therapy products for patients.

Currently, JUVENTAS owns a 1300㎡ research center in Beijing, a 1400㎡ institute complying GMP standard for immune cell therapy drug’s R&D transformation and production, also, our 7000㎡ GMP immune cell therapy drug production base is under construction.
On November 29, Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA) officially approved two applications of JUVENTAS’ new drug clinical trial for CNCT 19 Cell Injection (anti-CD19 Chimeric Antigen Receptor T Cell Injection) to treat relapsed or refractory acute lymphoblastic leukemia and relapsed or refractory invasive B-cell non-Hodgkin’s lymphoma.

Management Team